DYN - Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. retains a Strong Buy rating, driven by clinical progress in DM1 and DMD programs targeting significant unmet needs. DYN expects to file a BLA for z-rostudirsen in DMD exon 51 skipping patients in Q2 2026, with potential commercialization by Q1 2027. Top-line data from the phase 1/2 ACHIEVE REC study in DM1 is anticipated in Q1 2027, supporting future accelerated approval filings.
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 17 newly hired employees.
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function - - FORZETTO trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications - WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the initiation of the Phase 3 FORZETTO trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA conference - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 on track for Q2 2026; global confirmatory Phase 3 HARMONIA trial initiated - - New preclinical data to be presented at ASGCT underscore differentiated capability of clinically validated FORCETM platform to cross the blood-brain barrier - WALTHAM, Mass.
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) Director Jason Rhodes sold 272,049 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $20.06, for a total value of $5,457,302.94. Following the sale, the director directly owned 14,561 shares in the company, valued at $292,093.66.
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 18 new employees. The awards were made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
Darwin Wealth Management LLC decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 33.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 115,267 shares of the company's stock after selling 58,250 shares during the period. Darwin Wealth Management LLC owned 0.08%
Aberdeen Group plc raised its position in Dyne Therapeutics, Inc. (NASDAQ: DYN) by 99.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,108,145 shares of the company's stock after acquiring an additional 551,412 shares during the period. Aberdeen
Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings. Profitability This table compares Dyne Therapeutics and MediWound's net
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts -
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report)'s share price rose 4.4% during mid-day trading on Friday. The company traded as high as $18.39 and last traded at $18.5840. Approximately 898,531 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 2,203,674 shares. The stock had previously closed
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating expenses in 2025. Encouraging long-term cardiopulmonary data from the DELIVER trial of z-rostudirsen (DYNE-251) strengthens the bull case for DMD therapy. Initiation of the pivotal Phase 3 HARMONIA trial for DYNE-101 in DM1 marks a critical regulatory and value inflection point.
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes - - HARMONIA trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications - WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the initiation of the Phase 3 HARMONIA trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101), in individuals with myotonic dystrophy type 1 (DM1).